Tag: Nature Medicine
-
Immunotherapy for HIV: Early PD-1 Treatment Shows Potential for Drug-Free Viral Control
Overview: A new immunotherapy approach in HIV Researchers report promising safety data from the first-in-human trial of an anti-PD-1 antibody, budigalimab, in people living with HIV. The study, published in Nature Medicine, explored whether a cancer immunotherapy could be used at low doses to augment the immune system’s ability to control HIV without daily antiretroviral…
-
Immunotherapy Trial: PD-1 Inhibitor Budigalimab Shows Potential for Drug-Free HIV Control
New Immunotherapy Approach Sparks Hope for HIV Management Researchers have taken a bold step in the hunt for HIV strategies that could reduce or even eliminate the need for daily antiretroviral therapy (ART). A first-in-human, randomized, placebo-controlled Phase 1b trial published in Nature Medicine explored budigalimab, a monoclonal antibody that targets the PD-1 protein, a…
-
Immunotherapy for HIV: Early Trials of Anti-PD1 Drug Budigalimab Suggest Drug-Free Viral Control
Immunotherapy Offers a New Avenue in HIV Management Researchers are cautiously optimistic about a novel immunotherapy approach that could one day reduce or even eliminate the need for daily HIV medications. In a first-in-human Phase 1b trial, budigalimab, a monoclonal antibody that blocks the programmed cell death protein 1 (PD-1) pathway, was tested in people…
-
Typhoid and Invasive Salmonella Vaccine Shows Promise in Phase 1 Trial
promising Phase 1 results for a novel Typhoid and iNTS vaccine A new trivalent vaccine designed to protect against typhoid fever and invasive non-typhoidal Salmonella (iNTS) infections has demonstrated encouraging safety and immune responses in a Phase 1 human trial. Developed through a collaboration between the University of Maryland (UM) School of Medicine and Bharat…